Real world efficacy of immunotherapy in nonsmall cell lung cancer

The evolution of drug therapy in solid tumors primarily leads to the increase in cancer specific survival, but inevitably raises financial burden. So far, none of the countries can venture total reimbursement with all necessary contemporary drugs for all patients. Doubling of expenses for cancer drug therapy in Russia in 2019 allowed oncologists using the most expensive treatments in more than 70 % of patients.

Purpose: To evaluate efficacy of various treatment types of non‑small cell lung cancer in real clinical setting.

Material and methods. We included patients with histologically verified metastatic non‑small cell lung cancer without activating mutations treated with first or second line therapy in 2018 – 2019. In total 287 patients were included: 230 — for the first line efficacy analysis, 100 — for the second. Time to disease progression, overall survival and objective response rate were evaluated.

Results. The use of checkpoint inhibitors in accordance with all actual recommendations (first line pembrolizumab monotherapy in PD-L1 > 50 %, chemoimmunotherapy in first line or monotherapy in the second line irrespectively to PD-L1 status) decreased one‑year mortality from 61 % in 2018 to 33 % in 2019, but significantly increased financial cost (p < 0.000). Moreover, checkpoint inhibitors in combination with chemotherapy irrespectively of PD-L1 expression increased response rate (from 10 % and 21 % for monotherapy and platinum doublet, respectively, to 33,2 % for chemoimmunotherapy). PD‑1 inhibitors as monotherapy increased median time to disease progression (4,1 and 6,2 months for monotherapy with chemotherapy and platinum doublet, respectively, to 6,5 months and not achieved for chemoimmunotherapy and monotherapy with checkpoint inhibitors).

Conclusion. More than doubling of financial costs spent for non‑small cell lung cancer treatment allowed access to contemporary treatment for all patients. Such unprecedented measures significantly improved efficacy, including double decrease of one‑year mortality. Nevertheless, rational design of regional clinical guidelines interpretation is of great importance in accurate and effective use of the healthcare budget.

1. Под ред. А. Д. Каприна, В. В. Старинского, Г. В. Петровой Злокачественные новообразования в России в 2018 году (заболеваемость и смертность) М.: МНИОИ им. П. А. Герцена — филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2019. илл. 250 с. ISBN 978‑5‑85502‑243‑8

2. Лактионов К. К., Артамонова Е. В., Бредер В. В., Горбунова В. А., Моисеенко Ф. В., Реутова Е. В. и соавт. Практические рекомендации по лекарственному лечению немелкоклеточного рака легкого. Злокачественные опухоли: Практические рекомендации RUSSCO #3s2, 2019 (том 9). С. 32 – 48.

3. Клинические рекомендации Министерства здравоохранения Российской Федерации: Рак легкого [Электронны й ресурс] / ред. совет: А. А. Алахвердиев [и др.]. — Москва; 2019. — Режим доступа: http://www.oncology.ru/association/clinicalguidelines/2018/rak_legkogo_pr2018.pdf.

4. Siegel R, Ma J, Zou, Z, Jemal A. Cancer statistics, 2014. // CA Cancer J Clin. 2014; 64 (1): 9 – 29.

5. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). // Eur J Cancer. 2009; 45 (2): 228 – 247.

6. Gandhi L, Rodríguez‑Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F, Domine M, Clingan P, Hochmair MJ, Powell SF, Cheng SY, Bischoff HG, Peled N, Grossi F, Jennens RR, Reck M, Hui R, Garon EB, Boyer M, Rubio‑Viqueira B, Novello S, Kurata T, Gray JE, Vida J, Wei Z, Yang J, Raftopoulos H, Pietanza MC, Garassino MC, KEYNOTE ‑189, I. Pembrolizumab plus Chemotherapy in Metastatic Non‑Small‑ Cell Lung Cancer. // N Engl J Med; 2018; 378 (22); 2078 – 2092.

7. Borghaei H, Langer CJ, Gadgeel S, Papadimitrakopoulou VA, Patnaik A, Powell SF, Gentzler RD, Martins RG, Stevenson JP, Jalal SI, Panwalkar A, Yang JC, Gubens M, Sequist LV, Awad MM, Fiore J, Saraf S, Keller SM, Gandhi L. 24‑Month Overall Survival from KEYNOTE ‑ 021 Cohort G: Pemetrexed and Carboplatin with or without Pembrolizumab as FirstLine Therapy for Advanced Nonsquamous Non‑Small Cell Lung Cancer. // J Thorac Oncol. 2019; 14 (1): 124 – 129.

8. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, Johnson DH Paclitaxel‑carboplatin alone or with bevacizumab for non‑small‑ cell lung cancer. // N Engl J Med. 2006; 355 (24): 2542 – 2550.

9. Murakami S, Saito H, Kondo T, Oshita F, Yamada K. Phase II study of bevacizumab, cisplatin, and pemetrexed in advanced non‑squamous non‑small cell lung cancer (NS-NSCLC) with EGFR wild‑type. // J Exp Ther Oncol. 2019; 13 (2): 131 – 138.

10. Barlesi F, Scherpereel A, Rittmeyer A, Pazzola A, Ferrer Tur N, Kim JH, Ahn MJ, Aerts JG, Gorbunova V, Vikström A, Wong EK, Perez‑Moreno P, Mitchell L, Groen HJ Randomized phase III trial of maintenance bevacizumab with or without pemetrexed after first‑line induction with bevacizumab, cisplatin, and pemetrexed in advanced nonsquamous non‑small‑ cell lung cancer: AVAPERL (MO22089). // J Clin Oncol. 2013; 31 (24): 3004 – 3011.

11. Rittmeyer A, Scherpereel A, Gorbunova VA, Gervais R, Vikström A, Chouaid C, Chella A, Kim JH, Ahn MJ, Reck M, Pazzola A, Kim HT, Aerts J, Groen HJM, Morando C, Loundou A, Barlesi F. Effect of maintenance bevacizumab (Bev) plus pemetrexed (Pem) after first‑line cisplatin / Pem / Bev in advanced nonsquamous non‑small cell lung cancer (nsNSCLC) on overall survival (OS) of patients (pts) on the AVAPERL (MO22089) phase III randomized trial. // Journal of Clinical Oncology. 2013; 31 (15 _suppl): 8014 – 8014.

12. Reck M, Rodríguez‑Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A, Gottfried M, Peled N, Tafreshi A, Cuffe S, O'Brien M, Rao S, Hotta K, Vandormael K, Riccio A, Yang J, Pietanza MC, Brahmer JR. Updated Analysis of KEYNOTE ‑ 024: Pembrolizumab Versus Platinum‑Based Chemotherapy for Advanced Non‑Small‑ Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50 % or Greater. // J Clin Oncol. 2019; 37 (7): 537 – 546.

13. Reck M, Rodríguez‑Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A, Gottfried M, Peled N, Tafreshi A, Cuffe S, O'Brien M, Rao S, Hotta K, Leiby MA, Lubiniecki GM, Shentu Y, Rangwala R, Brahmer JR, KEYNOTE‑ 024, I. Pembrolizumab versus Chemotherapy for PD-L1‑Positive Non‑Small‑ Cell Lung Cancer. // N Engl J Med. 2016; 375 (19): 1823 – 1833.

14. Clarke SJ, Abratt R, Goedhals L, Boyer MJ, Millward MJ, Ackland SP. Phase II trial of pemetrexed disodium (ALIMTA, LY231514) in chemotherapy‑naïve patients with advanced non‑small‑ cell lung cancer. // Ann Oncol. 2002; 13 (5): 737 – 741.

15. Fossella FV, DeVore R, Kerr RN, Crawford J, Natale RR, Dunphy F, Kalman L, Miller, V, Lee JS, Moore M, Gandara D, Karp D, Vokes E, Kris M, Kim Y, Gamza F, Hammershaimb L. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non‑small‑cell lung cancer previously treated with platinum‑containing chemotherapy regimens. The TAX 320 Non‑Small Cell Lung Cancer Study Group. // J Clin Oncol. 2000; 18 (12): 2354 – 2362.

16. Borghaei H, Paz‑Ares L, Horn L, Spigel DR, Steins M, Ready NE, Chow LQ, Vokes EE, Felip E, Holgado E, Barlesi F, Kohlhäufl M, Arrieta O, Burgio MA, Fayette J, Lena H, Poddubskaya E, Gerber DE, Gettinger SN, Rudin CM, Rizvi N, Crinò L, Blumenschein GR, Antonia SJ, Dorange C, Harbison CT, Graf Finckenstein F, Brahmer JR. Nivolumab versus Docetaxel in Advanced Nonsquamous Non‑Small‑ Cell Lung Cancer. // N Engl J Med. 2015; 373 (17): 1627 – 1639.

17. Brahmer J, Reckamp KL, Baas P, Crinò L, Eberhardt WE, Poddubskaya E, Antonia S, Pluzanski A, Vokes EE, Holgado E, Waterhouse D, Ready N, Gainor J, Arén Frontera O, Havel L, Steins M, Garassino MC, Aerts JG, Domine M, Paz‑Ares L, Reck M, Baudelet C, Harbison CT, Lestini B, Spigel DR Nivolumab versus Docetaxel in Advanced Squamous‑ Cell Non‑Small‑ Cell Lung Cancer. // N Engl J Med. 2015; 373 (2): 123 – 135.

18. Herbst RS, Baas P, Kim DW, Felip E, Pérez‑Gracia JL, Han JY, Molina J, Kim JH, Arvis CD, Ahn MJ, Majem M, Fidler MJ, de Castro G, Garrido M, Lubiniecki GM, Shentu Y, Im E, Dolled‑Filhart M, Garon EB. Pembrolizumab versus docetaxel for previously treated, PD-L1‑positive, advanced non‑small‑ cell lung cancer (KEYNOTE ‑ 010): a randomised controlled trial. // Lancet. 2016 Apr 9;387 (10027):1540 – 1550.

19. Rittmeyer A, Barlesi F, Waterkamp D, Park K, Ciardiello F, von Pawel J, Gadgeel SM, Hida T, Kowalski DM, Dols MC, Cortinovis DL, Leach J, Polikoff J, Barrios C, Kabbinavar F, Frontera OA, De Marinis F, Turna H, Lee JS, Ballinger M, Kowanetz M, He P, Chen DS, Sandler A, Gandara DR, OAK, S. G. Atezolizumab versus docetaxel in patients with previously treated non‑small‑ cell lung cancer (OAK): a phase 3, open‑label, multicentre randomised controlled trial. // Lancet. 2017; 389 (10066): 255 – 265.

20. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, Zhu J, Johnson DH. Comparison of four chemotherapy regimens for advanced non‑small‑ cell lung cancer. // N Engl J Med. 2002; 346 (2): 92 – 98.

21. Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C, Serwatowski P, Gatzemeier U, Digumarti R, Zukin M, Lee JS, Mellemgaard A, Park K, Patil S, Rolski J, Goksel T, de Marinis F, Simms L, Sugarman KP, Gandara D. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy‑naive patients with advanced‑stage non‑small‑ cell lung cancer. // J Clin Oncol. 2008; 26 (21): 3543 – 3551.

22. Wang S, Hao J, Wang H, Fang Y, Tan L. Efficacy and safety of immune checkpoint inhibitors in non‑small cell lung cancer. // Oncoimmunology. 2018; 7 (8): e1457600.

23. Kim BJ, Kim JH, Kim HS. Survival benefit of immune checkpoint inhibitors according to the histology in non‑small‑ cell lung cancer: A meta‑analysis and review. // Oncotarget. 2017; 8(31): 51779–51785.